Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimum Dosage of Intravenous Lidocaine for Post-Operative Pain Control in Bariatric Bowel Surgery
NCT03095404Phase 1Withdrawn
- Sponsor
- McMaster University
- Start
- Oct 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial of Lidocaine Hydrochloride Injection, without epinephrine in postoperative pain (2 arms), sponsored by McMaster University. Primary endpoint: Evaluation of an intravenous lidocaine dosing schedule using 1mg/kg or 2mg/kg adjusted body weight at 5 days. Planned start Oct 2022; status: withdrawn.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03095404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095404.